ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,039.31
-0.47%
US Tech 100
20,833.20
0.00%
다우존스 지수
44,713.52
-0.31%
Bitcoin
105,030.89
1.25%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. RAPT Therapeutics Inc (RAPT) 시세

RAPT Therapeutics Inc

RAPT Therapeutics Inc (RAPT)

NASDAQ
1.17
0.00
(0.00%)
마감 30 1월 6:00AM
15분 지연
0.00
0.00
(0.00%)
시간외 거래: -
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
1.17
매수가
1.14
매도가
1.20
거래량
-
0.00 일간 변동폭 0.00
0.78925 52주 범위 27.35
market_cap
40.901M
전일 종가
1.17
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
3,870,020
발행 주식
34,958,253
배당수익률
-
주가수익률
-0.35
주당순이익(EPS)
-3.34
매출
-
순이익
-116.8M

RAPT Therapeutics Inc 정보

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX... RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.rapt.com
본부
Dover, Delaware, USA
설립됨
-
RAPT Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker RAPT. The last closing price for RAPT Therapeutics was US$1.17. Over the last year, RAPT Therapeutics shares have traded in a share price range of US$ 0.78925 to US$ 27.35.

RAPT Therapeutics currently has 34,958,253 shares in issue. The market capitalisation of RAPT Therapeutics is US$40.90 million. RAPT Therapeutics has a price to earnings ratio (PE ratio) of -0.35.

RAPT 최신 뉴스

추가 뉴스

Form 424B3 - Prospectus [Rule 424(b)(3)]

28 1월 2025
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

28 1월 2025
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

22 1월 2025
Edgar (US Regulatory)

Form 8-K - Current report

14 1월 2025
Edgar (US Regulatory)

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

09 1월 2025
GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

07 1월 2025
Edgar (US Regulatory)

Form 8-K - Current report

07 1월 2025
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

06 1월 2025
Edgar (US Regulatory)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering...

06 1월 2025
GlobeNewswire Inc.

Form D - Notice of Exempt Offering of Securities

04 1월 2025
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.02-1.680672268911.191.2451.11513128591.17125787CS
4-0.42-26.41509433961.591.7851.06513407901.31882909CS
12-1.57-57.2992700732.743.170.7892538700201.65550076CS
26-2.06-63.77708978333.233.320.7892518513621.70213745CS
52-24.87-95.506912442426.0427.350.7892514295303.91042761CS
156-18.99-94.196428571420.1632.450.789257166009.44780951CS
260-43.58-97.385474860344.7546.490.7892555416914.22835066CS

RAPT - Frequently Asked Questions (FAQ)

What is the current RAPT Therapeutics share price?
The current share price of RAPT Therapeutics is US$ 1.17
How many RAPT Therapeutics shares are in issue?
RAPT Therapeutics has 34,958,253 shares in issue
What is the market cap of RAPT Therapeutics?
The market capitalisation of RAPT Therapeutics is USD 40.9M
What is the 1 year trading range for RAPT Therapeutics share price?
RAPT Therapeutics has traded in the range of US$ 0.78925 to US$ 27.35 during the past year
What is the PE ratio of RAPT Therapeutics?
The price to earnings ratio of RAPT Therapeutics is -0.35
What is the reporting currency for RAPT Therapeutics?
RAPT Therapeutics reports financial results in USD
What is the latest annual profit for RAPT Therapeutics?
The latest annual profit of RAPT Therapeutics is USD -116.8M
What is the registered address of RAPT Therapeutics?
The registered address for RAPT Therapeutics is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the RAPT Therapeutics website address?
The website address for RAPT Therapeutics is www.rapt.com
Which industry sector does RAPT Therapeutics operate in?
RAPT Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
AALAmerican Airlines Group Inc
US$ 17.33
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.435
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.89
(0.00%)
0
AACGATA Creativity Global
US$ 0.8559
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 17.33
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.435
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.89
(0.00%)
0
AACGATA Creativity Global
US$ 0.8559
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 17.33
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.435
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.89
(0.00%)
0
AACGATA Creativity Global
US$ 0.8559
(0.00%)
0

RAPT Discussion

게시물 보기
Monksdream Monksdream 4 주 전
RAPT, under $2
👍️0
tbonaces80 tbonaces80 1 월 전
Buy this. Smart money in. 
👍️0
tbonaces80 tbonaces80 1 월 전
Gonna breakout above $2.11. Hold for major move. Shares gobbled on this wedge
👍️0
glenn1919 glenn1919 1 월 전
RAPT......................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 1 월 전
$2.20 + 20%
👍️0
tbonaces80 tbonaces80 1 월 전
Wainwright ups price to $10. This will be going parabolic 
👍️0
tbonaces80 tbonaces80 1 월 전
We go hard this week. Too many Capital firms bought in. Load the boat $6-$10 easy
👍️0
tbonaces80 tbonaces80 1 월 전
This will hit $6 easily. Analysts know. Huge funding.  Foully loaded. 
👍️0
PonkenPlonken PonkenPlonken 1 월 전
@tbonaces80 @Princess17
What do you two think about this?
150 million pp says massively misunderstood story? 140mn historical volume too...
👍️0
tbonaces80 tbonaces80 1 월 전


👍️0
tbonaces80 tbonaces80 1 월 전
Load zone. 
👍️0
Princess17 Princess17 1 월 전
👍🏻 looks good 
👍️0
tbonaces80 tbonaces80 1 월 전
Upgrade. Wells. Yup 
👍️0
PonkenPlonken PonkenPlonken 1 월 전
see chart and compare PP to market cap
must be massively misunderstood

also had a license agreement today
Regards
👍️0
bigbux1 bigbux1 1 월 전
What am I missing? They just did a private placement of 100,000,000 shares of common stock at a purchase price of $0.85 per share and this soars past 1.50?
👍️0
Mister Mr Mister Mr 1 월 전
Keep pumping! Let's go!!!
👍️0
glenn1919 glenn1919 1 월 전
rapt........................https://stockcharts.com/h-sc/ui?s=rapt&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 1 월 전
https://www.globenewswire.com/news-release/2024/12/23/3001133/0/en/RAPT-Therapeutics-Announces-150-Million-Private-Placement.html
wow!
market cap 30 million no discount
👍️0
Invest-in-America Invest-in-America 1 월 전
RAPT:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175569055
👍️0
tw0122 tw0122 1 월 전
RAPT up 15% news and TRAW also up $13.77 + 150% TRAW up big
👍️0
glenn1919 glenn1919 2 월 전
RAPT.........................https://stockcharts.com/h-sc/ui?s=RAPT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 월 전
RAPT under $3
👍️0
Monksdream Monksdream 5 월 전
RAPT new 52 week low
👍️0
Monksdream Monksdream 5 월 전
RAPT new 52 low
👍️0
Monksdream Monksdream 6 월 전
RAPT under $4
👍️0
Monksdream Monksdream 9 월 전
RAPT new 52 week
👍️0
Monksdream Monksdream 9 월 전
RAPT under $10
👍️0
tickersym tickersym 11 월 전
Bargin prices!! Lets go!!
👍️0
Stockexpertpro Stockexpertpro 11 월 전
RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK
👍️0
StockLogistics StockLogistics 2 년 전
Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”
👍️0
StockLogistics StockLogistics 3 년 전
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 년 전
12.16 gap fill over the next 14.5 weeks
👍️0
StockLogistics StockLogistics 3 년 전
15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.
👍️0
StockLogistics StockLogistics 3 년 전
A ton of insider buying last week
👍️0
StockLogistics StockLogistics 3 년 전
Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing
👍️0
Glider549 Glider549 4 년 전
It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.
👍️0
weasel4339 weasel4339 4 년 전
It's way up after hours bud
👍️0
Glider549 Glider549 4 년 전
Can't believe some of you did not take profits near the close.
Greed will kill ya.
👍️0
pennyfinder pennyfinder 4 년 전
Will do
👍️0
weasel4339 weasel4339 4 년 전
I'll keep n eye out. Let me knoe if u hear something about the price
👍️0
pennyfinder pennyfinder 4 년 전
Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.
👍️0
weasel4339 weasel4339 4 년 전
This considered dilution?
👍️0
pennyfinder pennyfinder 4 년 전
LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common
👍️0
make it happen make it happen 4 년 전
Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.
👍️0
pennyfinder pennyfinder 4 년 전
Offering AH or tomorrow pre
👍️0
make it happen make it happen 4 년 전
Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M
👍️0
StockLogistics StockLogistics 4 년 전
This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it
👍️0
Roadtojourney Roadtojourney 5 년 전
Not even 6 months old and already offering??
👍️0
crudeoil24 crudeoil24 5 년 전
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
👍️0
crudeoil24 crudeoil24 5 년 전
42.00 > hod.

RAPT
👍️0

최근 히스토리

NASDAQ
RAPT
RAPT Therapeutics
TG
VE4B
VanEck Durable High Divi...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지